News of Note—Sanofi's Dengvaxia, flu vaccines and more

In this week's news of note, a Philippine FDA official said Sanofi knew of Dengvaxia risks earlier than it disclosed, but a company executive denied the allegation. (Pixabay)

Here is some other vaccine news of note for the week.

> An examination of documents filed in Singapore showed that Sanofi Pasteur was aware in October 2016 that Dengvaxia shouldn’t be given to those who haven’t had dengue, according to a Philippine official. A company executive said the document outlined possible or "theoretical" risks. CNN article | Inquirer article 

> The WHO has recommended changing two flu strains currently included in flu vaccines for the next season, and an FDA advisory committee will determine whether to apply them for the U.S. WHO recommendation | FDA statement


Innovative and Flexible Solutions for an End-to-End Patient-Centric, Lean Supply Chain

The trend toward crafting patient-centric clinical trials hold great promise in supporting patients’ willingness and ability to participate in important clinical research. This webinar will explore how recent innovations in forecasting, supply pooling, decentralized processing, labeling, demand-led supply and direct-to-patient distribution are converging to create a next-generation clinical supply chain that is flexible, lean and most importantly patient-centric.

> Supported by a £4.7 million government award, the University of Liverpool is leading a collaborative project to develop a Zika vaccine suitable for pregnant women. Release

> Emergent BioSolutions and partner Valneva have advanced their Zika vaccine candidate into human testing. Release

> South Korea’s SK Chemicals, which recently licensed its cell-based flu vaccine technology to Sanofi, plans to spin off its vaccine business into a separate subsidiary. Korea Biomedical Review article

> The Association of the British Pharmaceutical Industry said a U.K. government proposal on the methodology used to assess immunization programs would make it harder for people to access vaccines. ABPI statement

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.